Clinical trial

Analgesic Efficacy of Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries

Name
Lumbar ESPB and PENG block
Description
The investigators are going to evaluate the postoperative analgesic efficacy of combined LESPB and PENG block after hip surgeries.
Trial arms
Trial start
2023-02-01
Estimated PCD
2023-08-01
Trial end
2023-12-01
Status
Completed
Phase
Early phase I
Treatment
Ultrasound guided L-ESPB and PENG block using Bupivacaine
Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
Arms:
Group A: L-ESPB and PENG
Other names:
Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block
Postoperative conventional analgesia in form of Acetaminophen
Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
Arms:
Group B: conventional analgesia
Other names:
Conventional analgesia
Size
24
Primary endpoint
Postoperative pain intensity
at 1 hour after the block
Postoperative pain intensity
at 3 hour after the block
Postoperative pain intensity
at 6 hour after the block
Postoperative pain intensity
at 12 hour after the block
Postoperative pain intensity
at 24 hour after the block
Eligibility criteria
Inclusion Criteria: * Patients aged 18-70 years old * American Society of Anesthesiologists (ASA) class I to III * Both sex * Scheduled for hip surgery. Exclusion Criteria: * Refusal to participate * Allergy to any of the study drugs * Bleeding disorder * Localized infection * Neurological disease * Renal impairment * Psychological disorders * Opioid dependent * Intellectual disability (patients unable to express pain with visual analogue) * Morbid obesity.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 24, 'type': 'ACTUAL'}}
Updated at
2023-12-28

1 organization

1 product

2 indications